Sanity Group is one of continental Europe's leading cannabis companies. Founded in Berlin in 2018 by Finn Hänsel and Fabian Friede, it has established itself in just a few years as the leading medical cannabis company in Germany, before expanding into Switzerland, the UK and other European markets.
Finn Hänsel and Fabian Friede created Sanity Group in 2018, in a German context still largely closed to recreational cannabis but already open to medical cannabis since 2017. Their positioning was clear from the outset: to develop pharmaceutical and wellness cannabinoid products, distributed via medical channels: pharmacies, doctors, hospitals.
The company quickly structured two complementary branches: Sanatio Pharma, dedicated to the import, distribution and development of medical cannabis in Germany, and VAAY, a consumer brand of CBD wellness products.
In February 2020, Sanity Group completes the largest cannabis fundraising in Europe at the time: €20 million in Serie A, led by Calyx and HV Holtzbrinck Ventures. Notable investors include Casa Verde Capital (Snoop Dogg's fund) and TQ Ventures (Justin Bieber's manager Scooter Braun's fund).
In September 2022, British American Tobacco acquired a minority stake, a strong signal of the tobacco giants' interest in the cannabis market.
In June 2024, NASDAQ-listed Canadian producer Organigram invests 14 million euros for a minority stake, as part of a strategic supply agreement.
With around 10% of the German medical cannabis market, Sanity Group distributes its products via over 2,000 pharmacies working with around 5,000 doctors in Germany. Its avaay medical brand holds the second position in the German market, with accelerated growth since the partial legalization of recreational cannabis in Germany in April 2024, which generated a 30 to 50% increase in medical prescriptions.
Sanity Group participates in the pilot program for the controlled sale of recreational cannabis in the Swiss canton of Basel-Landschaft via its brand Grashaus Project, with an operational sales outlet and plans for expansion in the Swiss retail sector.
In the UK, Sanity Group entered into a partnership in 2024 with Curaleaf Laboratories to develop new medical cannabis formulations for UK prescribers, with the first products expected in the first quarter of 2026.
In 2025, Sanity Group finalizes a major strategic agreement with Organigram: the company is valued at up to 250 million euros, with 130 million euros paid upfront and up to a further 120 million conditional on performance until March 2027. Finn Hänsel confirms that the company will continue to focus on the pharmaceutical segment and pharmacy distribution.
Sanity Group has its headquarters in Berlin and a logistics and processing site near Frankfurt. It remains unlisted on the stock exchange.
Sanity Group has announced a new distribution partnership with Swiss cannabis operator Astrasana Holding AG, thereby strengthening its presence in the Swiss market, which...
Curaleaf Laboratories, one of the UK's leading manufacturers of medical cannabis products, has signed an agreement with Sanity Group, the Berlin-based company that has just...
Canadian cannabis producer Organigram Global has announced its intention to acquire Germany's «second largest» medical cannabis company, Sanity Group, in...
The Federal Institute for Agriculture and Food (BLE) has blocked the pilot project for the legal sale of cannabis in Frankfurt. The project, submitted in December 2024, was...
Six months after the opening of Europe's first legal cannabis store in Switzerland, experts are reporting trends in favor of regulated sales and more...
Organigram Holdings is investing €14 million ($14.9 million) in Berlin-based cannabis operator Sanity Group, as the Canadian producer looks to expand its...
Germany's long-awaited «second pillar», which would implement an adult-use cannabis pilot project model along the lines of the...
British American Tobacco (BAT) recently announced a substantial investment of nearly $125 million in Canadian cannabis producer Organigram, and has just...
Europe's first legal cannabis dispensary is set to open by the end of the year as part of the sixth adult-use cannabis pilot project in...
Sanity Group, one of Germany's largest cannabis companies, has signed an agreement with North America's leading cannabis retailer,...
Initially scheduled to be submitted to the European Commission by the end of 2022, Germany's plan to legalize cannabis will not be submitted to the European...
Last month, 20 cannabis companies from several countries sent an open letter to the European Commission. The letter was signed by, among others,...
British American Tobacco (BAT) has taken a non-controlling minority stake in German cannabis company Sanity Group for an undisclosed amount, it announced Monday...
Supermodel and businesswoman Heidi Klum reportedly recently met Burkhard Blienert, Germany's new drugs commissioner, at a private meeting and expressed her support...
As Europe embraces medical cannabis, the landscape of medical cannabis prescriptions on the Old Continent has different characteristics to those in the US....
Sanity Group, a Berlin-based cannabis start-up, announced in February that it had raised 20 million euros to finance its development. Among the investors were Scooter Braun, who...
